GSK has signed an option agreement with Duality Biologics worth over US$1 B to obtain an exclusive license to develop and commercialise antibody-drug conjugate, DB-1324. DB-1324 is built on DualityBio’s Duality Immune Toxin Antibody Conjugate (DITAC) platform and is currently in preclinical development against a gastrointestinal cancer target. The following day, GSK then partnered with Rgenta Therapeutics for the discovery and development of novel RNA-targeted small molecule splice modulators for multiple disease areas including oncology, paying US$46 M upfront and up to US$500 M per target.